Author:
Ziółkowski Piotr,Woźniak Marta,Mansour Ahmad,An Yu,Weber Georg F.
Abstract
Abstract
Background
Papillomas of the breast pose challenges for treatment decisions as their risk for transformation to breast cancer is low but not negligible. To spare low-risk patients the burden of substantial treatment side effects, prognostic indicators are needed for cancerous progression. The secreted metastasis mediator Osteopontin (OPN) is a marker for breast cancer aggressiveness, and its variants are prognosticators for transformation in diverse premalignant breast lesions. Here, we test whether the presence of OPN-c or OPN-exon-4 in papillomatous lesions may reflect progression risk.
Methods
By immunohistochemistry, we analyze OPN-c and OPN-exon-4 in papillomas from 114 women as well as correlations between staining and progression. In departure from prior spliced OPN biomarker publications, we utilize novel monoclonal antibodies.
Results
Fewer than 5% of OPN-c pathology score 0–1 (intensity) versus almost 18% of score 2–3 experienced cancer in follow-up. Nine of 12 women, who progressed, had pathology scores of 2–3 for OPN-c intensity at the time of initial diagnosis, and none had a score of 0. When developing a combined risk score from intensity plus percent positivity for OPN-c, the progression risk for patients with low score was 3.2%, for intermediate score was 5.7%, and for high score was 18.8%. Papillomas in patients, who were later diagnosed with cancer in the contralateral breast, displayed stronger staining positivity than non-progressors.
Conclusion
OPN splice variant immunohistochemistry on biopsies of breast papillomas will allow counseling of the patients on their risk to develop breast cancer at a later time.
Funder
National Cancer Institute
Marlene Harris-Ride Cincinnati
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Lewis JT, Hartmann LC, Vierkant RA, Maloney SD, Shane Pankratz V, Allers TM, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol. 2006;30(6):665–72.
2. Esmayil H, Abayazeed S, Hajaj M. Audit on intraductal papilloma of the breast: upgrade rate, management pitfalls, and updated guidelines in a Tertiary Health Care Center. Cureus. 2021;13(10): e18763.
3. Ni YB, Tse GM. Pathological criteria and practical issues in papillary lesions of the breast—A review. Histopathology. 2016;68(1):22–32.
4. Kraus FT, Neubecker RD. The differential diagnosis of papillary tumors of the breast. Cancer. 1962;15:444–55.
5. Kulka J, Madaras L, Floris G, Lax SF. Papillary lesions of the breast. Virchows Arch. 2021;480:65.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献